Program
ABBV-295
A development code.
In AbbVie's pipeline, Long-Acting Amylin Analog
. Its studies are mostly in Obesity · Psoriasis, led by AbbVie.
Furthest: phase 2, since Aug 4, 20265 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 54 open or running | phase 2since Aug 4, 2026 | Nov 19, 2025 | Dec 2026phase 1 · NCT07514260 |
- Named in AbbVie’s own pipeline as
ABBV-295
, phase 2, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2025First study: phase 1 study in ObesityFirst studyNCT07291232 · 80 enrolled · United States
- Feb 11, 2026Phase 1 study in Healthy VolunteerNCT07414784 · 20 enrolled · United States
- Mar 31, 2026Phase 1 study in Healthy VolunteerNCT07514260 · 24 enrolled · United States
- Aug 4, 2026Phase 2 study in ObesityPhase 2 reachedNCT07752979 · 360 planned · United States, Puerto Rico
- Nov 6, 2026Phase 2 study in PsoriasisNCT07933536 · 105 planned
Ahead
- Dec 2026Primary completion: phase 1 study in Healthy VolunteerNCT07514260
- Apr 2027Primary completion: phase 1 study in ObesityNCT07291232
- Mar 2028Primary completion: phase 2 study in ObesityNCT07752979
- Dec 2028Primary completion: phase 2 study in PsoriasisNCT07933536
TargetBeta
“Long-Acting Amylin Analog”the company's pipeline, read by Claude · source
Other programs on CALCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cagrilintide | Novo Nordisk | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| petrelintiderule | Zealand Pharma | phase 3 | 11 |
| PF-08653945 | Pfizer | phase 2 | 2 |
| GUB014295 | AbbVie | phase 1 | 1 |
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933536Psoriasis | 2 | Not yet recruiting | Dec 2028 | 105 |
| NCT07752979Obesity · United States, Puerto Rico | 2 | Recruiting | Mar 2028 | 360 |
| NCT07514260Healthy Volunteer · United States | 1 | Active, not recruiting | Dec 2026 | 24 |
| NCT07414784Healthy Volunteer · United States | 1 | Completed | Aug 4, 2026 | 20 |
| NCT07291232Obesity · United States | 1 | Active, not recruiting | Apr 2027 | 80 |
How it is read
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.